PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

Recent News

  • PreveCeutical Confirms Receipt of CBD For Sol-Gel

    Vancouver, British Columbia--(Newsfile Corp. - July 13, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") is pleased to inform that the cannabis product required for its cannabinoid Sol-Gel program to address the COVID-19 pandemic (the "COVID-19 Sol-gel") (News Release dated May 4, 2020), was received by...

    2020-07-13 7:00 AM ET
  • PreveCeutical Announces Filing of Provisional Patent Application

    Vancouver, British Columbia--(Newsfile Corp. - July 8, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on July 1, 2020, entitled "Peptides and Uses Thereof", application number 2020902233, with the aim...

    2020-07-08 7:00 AM ET
  • PreveCeutical Announces Stability Data from CBD Sol-gel Product Development Program

    Vancouver, British Columbia--(Newsfile Corp. - July 6, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce successful results from its Cannabinoid sol-gel product development program.We have successfully conducted a three-month physico-chemical stability test on cannabinoid sol-gel formulations designed for nose-to-brain ("NTB") delivery.The...

    2020-07-06 7:00 AM ET
  • PreveCeutical Announces Promising 3D Liver Tissue Testing of Potential Therapy for Diabetes and Obesity

    Vancouver, British Columbia--(Newsfile Corp. - June 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it has successfully designed, screened and shortlisted a panel of smart-siRNA constructs with potent gene silencing activity (in vitro) in its Dual Gene Therapy Research Program.This further...

    2020-06-29 7:00 AM ET
  • PreveCeutical Executes Agreement for Development of CBD Sol-Gel Nasal Spray Formulation as a Potential Treatment for SARS-CoV-2 Infection

    Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that on June 18th, 2020, it has contracted UniQuest Pty Ltd. ("UniQuest") to apply the cannabinoid sol-gel ("CBD Sol-Gel") technology to develop a nasal spray formulation as a...

    2020-06-22 12:23 PM ET
  • PreveCeutical Announces Sol-Gel Chemistry Fingerprinting SOPs

    Vancouver, British Columbia--(Newsfile Corp. - June 17, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it has successfully developed 'Standard Operating Procedures' ("SOPs") allowing for the chemical fingerprinting (profiling) of cannabinoids present in its extracts which can be used to formulate...

    2020-06-17 7:00 AM ET
  • PreveCeutical Issued Statement Regarding Promotional Activity

    Vancouver, British Columbia--(Newsfile Corp. - June 16, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") provides the following information about certain promotional activities at the request of OTC Markets.On June 15, 2020, the Company was notified by OTC Markets that recently, certain materials promoting PreveCeutical's common...

    2020-06-16 7:13 PM ET
  • PreveCeutical Announces Further Successful Results from The Sol-Gel Program Final Report

    Vancouver, British Columbia--(Newsfile Corp. - June 15, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") is pleased to announce the successful completion of its cannabinoid sol-gel program (the "Sol-gel Program") with the University of Queensland ("UQ") and UniQuest Pty Ltd. ("UniQuest).The final report confirms the successful chemical profiling of...

    2020-06-15 7:00 AM ET